Delgocitinib

Delgocitinib, sold under the brand name Corectim among others, is a medication used for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.^[3] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis.^[3] In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib fast track designation for topical treatment of adults with moderate to severe chronic hand eczema.^[4]

Delgocitinib

Clinical data
Trade names	Corectim, others
Other names	JTE-052; JTE-052A
ATC code	D11AH11 (WHO)
Legal status
Legal status	EU: Rx-only[1][2] JP: Rx-only
Identifiers
IUPAC name 3-[(3S,4R)-3-Methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
CAS Number	1263774-59-9
PubChem CID	50914062
DrugBank	DB16133
ChemSpider	59718502
UNII	9L0Q8KK220
KEGG	D11046
CompTox Dashboard (EPA)	DTXSID401336933
Chemical and physical data
Formula	C16H18N6O
Molar mass	310.361 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
InChI InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1 Key:LOWWYYZBZNSPDT-ZBEGNZNMSA-N

Delgocitinib works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.^[5]

Society and culture

Legal status

In July 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Anzupgo, intended for the treatment of chronic hand eczema.^[1][6] The applicant for this medicinal product is LEO Pharma A/S.^[1] Anzupgo was authorized for medical use in the European Union in September 2024.^[1][2]